Literature DB >> 27389394

Metachromatic Leukodystrophy: An Assessment of Disease Burden.

Florian S Eichler1, Timothy M Cox2, Eric Crombez3, Christine Í Dali4, Alfried Kohlschütter5.   

Abstract

Metachromatic leukodystrophy is accompanied by severe motor and cognitive dysfunction. This is the first survey of metachromatic leukodystrophy caregiver perspectives to identify relevant clinical/quality-of-life outcomes for patients/caregivers. Interviews and 1 focus group were conducted with 30 caregivers representing 23 patients. Caregivers were asked about their experiences, including diagnostic process, signs/symptoms, symptoms affecting caregivers' and patients' lives, and treatment priorities. Caregivers reported loss of physical autonomy, weight loss, limited social relationships, frequent crying, and challenging sibling relationships. Most troublesome symptoms were immobility (9/30) and respiratory difficulties (6/30). Health care visits were frequent: 8/22 patients had experienced ≥11 hospitalizations since diagnosis, and 14/22 caregivers reported that these lasted ≥4 days. Caregivers also experienced work problems, feelings of fear/sadness, and loss of social relationships. Caregivers/physicians consider a therapy that could improve decline in mobility, pain, cognitive ability, communication, or food intake as conferring the greatest benefit. In conclusion, a so-far-unreported physical/economic burden in these families is presented.
© The Author(s) 2016.

Entities:  

Keywords:  burden of illness; caregivers; metachromatic leukodystrophy; quality of life; survey

Mesh:

Year:  2016        PMID: 27389394     DOI: 10.1177/0883073816656401

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

1.  Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies.

Authors:  Laura A Adang; Omar Sherbini; Laura Ball; Miriam Bloom; Anil Darbari; Hernan Amartino; Donna DiVito; Florian Eichler; Maria Escolar; Sarah H Evans; Ali Fatemi; Jamie Fraser; Leslie Hollowell; Nicole Jaffe; Christopher Joseph; Mary Karpinski; Stephanie Keller; Ryan Maddock; Edna Mancilla; Bruce McClary; Jana Mertz; Kiley Morgart; Thomas Langan; Richard Leventer; Sumit Parikh; Amy Pizzino; Erin Prange; Deborah L Renaud; William Rizzo; Jay Shapiro; Dean Suhr; Teryn Suhr; Davide Tonduti; Jacque Waggoner; Amy Waldman; Nicole I Wolf; Ayelet Zerem; Joshua L Bonkowsky; Genevieve Bernard; Keith van Haren; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2017-08-20       Impact factor: 4.797

2.  Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi).

Authors:  Daphne H Schoenmakers; Shanice Beerepoot; Sibren van den Berg; Laura Adang; Annette Bley; Jaap-Jan Boelens; Francesca Fumagalli; Wim G Goettsch; Sabine Grønborg; Samuel Groeschel; Peter M van Hasselt; Carla E M Hollak; Caroline Lindemans; Fanny Mochel; Peter G M Mol; Caroline Sevin; Ayelet Zerem; Ludger Schöls; Nicole I Wolf
Journal:  Orphanet J Rare Dis       Date:  2022-02-14       Impact factor: 4.123

3.  An international study of caregiver-reported burden and quality of life in metachromatic leukodystrophy.

Authors:  Caroline Sevin; Magalie Barth; Alexandra Wilds; Abena Afriyie; Markus Walz; Annamarie Dillon; Kenneth Howie; Francis Pang
Journal:  Orphanet J Rare Dis       Date:  2022-09-02       Impact factor: 4.303

4.  Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy.

Authors:  F Eichler; Caroline Sevin; M Barth; F Pang; K Howie; M Walz; A Wilds; C Calcagni; C Chanson; L Campbell
Journal:  Orphanet J Rare Dis       Date:  2022-10-04       Impact factor: 4.303

Review 5.  Ethical Issues in Care and Treatment of Neuronal Ceroid Lipofuscinoses (NCL)-A Personal View.

Authors:  Alfried Kohlschütter
Journal:  Front Neurol       Date:  2021-06-25       Impact factor: 4.003

6.  Navigating the U.S. health insurance landscape for children with rare diseases: a qualitative study of parents' experiences.

Authors:  Tai L S Pasquini; Sarah L Goff; Jennifer M Whitehill
Journal:  Orphanet J Rare Dis       Date:  2021-07-15       Impact factor: 4.123

7.  Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy.

Authors:  Steven Troy; Margaret Wasilewski; Jack Beusmans; C J Godfrey
Journal:  Clin Pharmacol Ther       Date:  2020-02-25       Impact factor: 6.875

8.  Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.

Authors:  Francesca Fumagalli; Valeria Calbi; Maria Grazia Natali Sora; Maria Sessa; Cristina Baldoli; Paola Maria V Rancoita; Francesca Ciotti; Marina Sarzana; Maddalena Fraschini; Alberto Andrea Zambon; Serena Acquati; Daniela Redaelli; Vanessa Attanasio; Simona Miglietta; Fabiola De Mattia; Federica Barzaghi; Francesca Ferrua; Maddalena Migliavacca; Francesca Tucci; Vera Gallo; Ubaldo Del Carro; Sabrina Canale; Ivana Spiga; Laura Lorioli; Salvatore Recupero; Elena Sophia Fratini; Francesco Morena; Paolo Silvani; Maria Rosa Calvi; Marcella Facchini; Sara Locatelli; Ambra Corti; Stefano Zancan; Gigliola Antonioli; Giada Farinelli; Michela Gabaldo; Jesus Garcia-Segovia; Laetitia C Schwab; Gerald F Downey; Massimo Filippi; Maria Pia Cicalese; Sabata Martino; Clelia Di Serio; Fabio Ciceri; Maria Ester Bernardo; Luigi Naldini; Alessandra Biffi; Alessandro Aiuti
Journal:  Lancet       Date:  2022-01-22       Impact factor: 79.321

9.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.